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Introduction
Carcinoma of the prostate is the most common 
noncutaneous cancer in males, and the second most 
common cause of cancer deaths in males.[1] Its incidence 
rises significantly after the age of 50 years, and this 
cancer is diagnosed in one in six men during their 
lifetime. Multiple etiological factors are implicated in 
the development of prostate cancer. Increasing age, a 
family history of disease, diet, and genetic factors have 
all been linked.
Among the most striking factors related to the 
development of prostate cancer, is race. Significantly, 
higher rates of prostate cancer are seen in native ethnic 
African males compared to Caucasian, Hispanic, and 
Asian males. Age-adjusted incidence rates (between 
2002 and 2006) were 231.9 per 100,000 African Americans 
versus 146.3 per 100,000 in Caucasians.[1] This made the 
incidence among the American native ethnic African men 
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Prostate cancer is the most common noncutaneous cancer in males. Men of African origin are at a significantly higher risk as 
reflected in the higher incidence and mortality rates in this racial group. Metastases incidence increases parallel to serum levels 
of prostate-specific antigen (PSA), contributing significantly to morbidity and mortality. Staging of the disease involves bone 
scans, which are sensitive in detecting skeletal metastases. Suggestions that these scans may be omitted in some situations in 
patients with low prostate specific antigen levels have drawn attention to the matter. In this case-control study, using radiology and 
pathology records, a registry of prostate cancer patients recorded as being of dark-skinned ethnicity was obtained. Images were 
presented to image reviewers blinded to the PSA level, to determine the presence of skeletal metastases. The risk factor for the 
outcome of interest (skeletal metastases) was PSA level above 20 ng/mL. The reliability of image reporting was also assessed. 
Of the 122 patients, skeletal metastases were present in 50 (41%) while these were absent in 72 (59%). The prevalence of 
metastases among the high PSA group was 55.9% [95% confidence interval (CI) 44.1–67.7%] and among the normal/low PSA 
group was 22.2% (95% CI 11.1–33.3%). The odds ratio (OR) for skeletal metastases in the exposed (high PSA) group was 
4.4 (95% CI, 2.01–9.78.) Intraobserver agreement on image interpretation was 88.5% with a Kappa statistic of 0.76. A relatively 
higher prevalence of skeletal metastasis is seen in regional dark-skinned African males with prostate cancer at both low and high 
prostate specific antigen levels. Bone scanning in this population should therefore, be considered even at PSA levels below 20 ng/mL.
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1.6 times higher than White men. In addition, the death 
rate among African Americans was 2.4 times higher than 
Caucasians in the same time period (53.6 versus 26.3 per 
100,000.) The differences in the incidence and mortality 
are greater still, when comparing the rates in African 
Americans to those among Hispanics, American Indians, 
and Asians suggesting that African Americans are not 
just at a higher risk of development of prostate cancer 
but also appear to develop more aggressive disease.
Prostate cancer is the most common cancer in Africa 
and sub-Saharan Africa. In Eastern Africa, age-adjusted 
incidence rates for prostate cancer are the second highest 
in this region after Kaposi sarcoma and esophageal 
carcinoma. The disease burden in Africa appears to be 
significant.[2]
Prostate-specific antigen (PSA) is produced in 
the prostatic epithelium but also by tumor cells. 
A combination of increased cell burden and distorted 
glandular architecture allowing the escape of prostate 
specific antigen into systemic circulation is responsible 
for the increased levels of prostate specific antigen in 
prostate cancer.
The skeletal system is one of the most common sites 
of metastasis, found in approximately 85% of patients 
dying from prostate cancer. These metastases are 
predominantly osteoblastic.
The bone scan (bone scintigraphy) is the most commonly 
performed procedure for whole-body screening and 
assessment of skeletal metastasis [Figure 1]. As a baseline 
investigation, it stages disease, demonstrates the extent 
of the disease where metastases exist, and provides a 
benchmark for follow-up scans when assessing response 
to treatment. The technique provides complementary 
information to the anatomical information provided by 
radiography, by demonstrating the metabolic changes 
induced by bone pathology. Due to the osteoblastic 
nature of prostate cancer metastases, metastatic 
deposits manifest as areas of increased tracer uptake. In 
extensive metastatic disease burden, diffuse uptake is 
seen throughout the axial skeleton giving a “superscan” 
appearance. Although the technique is relatively less 
specific, it has substantially higher sensitivity compared 
to radiography. Accurate disease staging can lead 
to more appropriate decision-making and advice to 
patients. Management differs significantly in patients 
with metastatic disease where the goal of therapy is 
palliative, symptom control, and disease suppression, 
versus eradication of the disease.
Performing bone scans in patients with PSA levels below 
20 ng/mL remains a gray area in clinical practice. The 
American Urology Association guidelines in its best 
practice statement of 2013 states that bone scans should 
be considered at PSA levels below 10 ng/mL if the 
tumor’s Gleason score is 8 or more or there is locally 
advanced disease (≥T3).[3] By contrast, guidelines by the 
European Association of Urology state that in locally 
advanced disease or poorly differentiated tumors, 
bone scans should be performed regardless of the PSA 
value.[4] The Japanese Urological Association suggests 
that bone scans may be eliminated when PSA levels are 
less than 10 ng/mL in patients with well- differentiated 
to moderately differentiated cancers.[5] A systematic 
review examined the findings from 48 research 
reports, 23 of which correlated baseline bone scan 
findings as well as PSA levels. Out of 8,644 patients, 
16.8% had metastases. Detection rates were 2.3%, 
5.3%, and 16.2% in patients with PSA levels less than 
10 ng/mL, 10.1–19.9 ng/mL, and 20 to 49.9 ng/mL, 
respectively.[6] This meta-analysis may be taken as a 
global overview. However, men in the east African 
region may be considered at a higher risk of developing 
skeletal metastases on the basis of ethnicity or other 
factors, based on the observation of a higher incidence 
of and more aggressive prostate cancer in other dark 
skinned populations worldwide. The present study was 
undertaken so as to generate data on prostate cancer 
metastasis to inform local and regional clinical practices.
Figure 1: Bone scan images depicting normal uptake (left), 
metastatic disease (middle), and a superscan (right)
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Materials and Methods
Based on a hypothesis that metastasis is more common 
than the global estimate in our population, a sample size 
calculation determined that a sample size of 120 (40 cases 
and 80 controls) were required to detect an odds 
ratio (OR) difference of 4 between patients with mildly 
elevated PSA (<20 ng/mL) and high PSA (≥20 ng/mL), 
at 91% power. This was derived from the pilot study data 
entered into a power and sample size calculator (http://
biostat.mc.vanderbilt.edu/PowerSampleSize. Approx. 
date of last access: 2012 December 20) where it was shown 
that to detect a low OR at a high power, a moderate 
number of cases were required [see Appendix 1.] Patients 
with histologically confirmed prostate cancer who had a 
bone scan between August 2011 and January 2013 at the 
Aga Khan University Hospital, Nairobi, Nairobi County, 
Kenya were consecutively collected for this retrospective 
case-control study, which was approved by the Research 
Ethics Committee (Ref No: 2012/REC-08(V2). Cases were 
defined as patients with histologically proven prostate 
cancer with skeletal metastases. Controls were defined 
as patients with histologically proven prostate cancer 
without skeletal metastases. The risk factor for outcome 
of interest (skeletal metastases determined by bone scan) 
was a PSA level greater than or equal to 20 ng/mL. 
Inclusion criteria included native ethnic African patients 
with histologically confirmed prostate cancer and a 
serum PSA test within 3 months of the bone scan who 
underwent bone scan for disease staging. Cases with 
bone metastases due to malignancy other than prostate 
cancer, posttherapy follow-up bone scans, equivocal 
cases without complementary images, and bone scans 
reported by a radiologist other than the nuclear physician 
were excluded from the study.
An initial listing of potentially eligible cases was acquired 
from the departmental patient register. The indication 
for the scan was confirmed from the radiology request 
form. In the few instances where this information was 
not provided, confirmation of the scan indication was 
made from the patient’s file. Following the collection of 
these data, the listing of cases was cross-referenced with 
the pathology department records to obtain details of 
histopathology where it was performed at the hospital. 
Pathology reports from other hospitals were included 
where available. Data collection began with the most 
recently performed bone scans to assess prostate cancer 
skeletal metastases, and proceeded retrospectively. The 
sampling of patients was stratified into two groups: 
those with mildly elevated or normal PSA (less than 
20 ng/mL,) and those with highly elevated PSA (greater 
than 20 ng/mL). The total number of patients acquired 
was only slightly greater than the desired sample size; 
therefore, sampling was nonrandom, and all eligible 
cases were included in the analysis. PSA levels were 
routinely collected from the patients prior to the bone 
scan. The patients’ ethnicities were confirmed from the 
patient registration section of the respective patient files 
where this information is routinely recorded according 
to hospital administrative procedures.
Data including patient identifiers were collected by 
one investigator. Details including the patient’s name, 
hospital number, and PSA level were entered into 
a primary data collection table and each record was 
coded, providing anonymity of the patient dataset and 
achieving a blinding of subjects to the image reviewers. 
Coded images were presented to the image reviewers 
who entered the data into a separate data collection 
table.
Technetium-99 methylene diphosphonate (99mTc-MDP) 
whole-body bone scans were performed on a dual 
head gamma camera (Millennium MG, GE Medical 
Systems, Milwaukee, WI, United States) 3–4 h following 
intravenous (IV) injection of 99mTc-MDP.
Image acquisition time for a whole-body scan was 
typically 20 min (camera speed of 11 cm/s); however, 
these varied depending on the amount of activity 
injected. Lower injected activities require a longer scan 
time. A matrix of 1024 × 256 was used with a low-energy 
high-resolution collimator (GE Medical Systems, 
Milwaukee, WI, United States). If necessary, spot views 
of an area of interest were acquired. Five hundred 
thousand counts were obtained of this site.
Images were analyzed by a nuclear physician (expert 
reviewer) with over 15 years of experience in nuclear 
medicine, and a registrar with cumulative total of 
5 months training in nuclear medicine. The coded images 
were uploaded onto the hospital picture archiving and 
communication system (PACS) to a folder specific for the 
purposes of the study. Through this system, images were 
presented to the image reviewers using Agfa® PACS 
and image viewing software (Mortsel, Belgium) on a 
high-resolution viewing monitor. The image reviewers 
were blinded to the results of the PSA. In cases with 
metastatic disease, sites of skeletal metastases were 
listed by the nuclear physician. Results of the nuclear 
physician’s repeat report were compared with the 
original so as to determine intraobserver variability, and 
comparison between the registrar’s report with the nuclear 
physicians repeat report to test interobserver variability. 
For comparison with PSA levels, the analysis was based 
on the expert reviewer’s repeat report. In equivocal cases, 
the image reviewers were provided with complementary 
images in the same coded manner.
PSA levels in patients with and without skeletal 
metastases and summary statistics for the distribution 
[Downloaded free from http://www.wjnm.org on Monday, March 2, 2020, IP: 130.159.82.155]
Qureshi, et al.: Prostate-specific antigen as a risk factor for skeletal metastasis
World Journal of Nuclear Medicine/Vol 16/Issue 1/January-March 2017 29
of PSA levels were calculated. Potential statistical 
associations between PSA and skeletal metastases were 
estimated using Chi-square statistics. OR of skeletal 
metastases between low and high PSA groups were 
calculated. To determine the prevalence of skeletal 
metastases in patients with PSA below 20 ng/mL a 
two-sample test for proportions was applied using the 
global estimate of 3.5% for comparison.[6] Assessment 
of intraobserver and interobserver agreement for 
bone scans was quantified using Cohen’s kappa and 
percentage of agreement.
Results
Within the 122 patient data sets included, 50 (41%) 
were found to have skeletal metastases while 72 (59%) 
had no skeletal metastases detectable on bone scan. 
Sixty-eight of the 122 PSA values (55.7%) were greater 
than or equal to 20 ng/mL while 54 patients (44.3%) 
were considered “unexposed” on the basis of PSA level 
of below 20 ng/mL.
Among patients with and without skeletal metastases, 
the PSA levels are summarized in Table 1 and Figure 2. 
To illustrate the actual range of PSA values in the 
sample population, the mean PSA in the “unexposed” 
group (PSA less than 20 ng/mL) was 10.2 ± 5.0 ng/mL 
(1–19.9 ng/mL) and the median PSA was 10 ng/mL. Within 
the “exposed” group (PSA greater than 20 ng/mL), the 
mean PSA was 441.4 ± 86.0 ng/mL (20–7000 ng/mL). 
The median PSA value was 86 ng/mL.
In the present study, the OR for skeletal metastasis 
was 4.4 [95% confidence interval (CI), 2.0–9.8] in the 
exposed (high PSA) group. The prevalence of metastases 
among this high PSA group was 55.9% (44.1–67.7%) 
and 22.2% (11.1–33.3%) among the normal or low PSA 
group. A two-sample test of proportions was used to 
compare these proportions with global estimates of 
42.6% and 3.5%, respectively, for the high PSA group 
and the normal or low PSA group. The prevalence 
of metastases among the high PSA group differed 
by 13.3% (95% CI, 1.2–25.4%; P = 0.031) compared 
to the global estimate. Among the low PSA group, 
the prevalence differed by 18.7% (95% CI, 7.6–29.8%; 
P = 0.001) from the estimated global average.
The sites of skeletal metastases varied, with the spine, 
pelvis, and rib cage representing the most common 
sites. These data are summarized in a bar graph format 
[Figure 3].
Intraobserver and interobserver agreement of reporting 
was performed using kappa statistics. There was an 
88.5% agreement between the expert reviewer’s original 
and repeat reports, giving a kappa value of 0.76, 
indicating substantial agreement. Agreement between 
the registrar and expert reviewer reports was 85.3%, 
with a kappa value of 0.70, also indicating substantial 
agreement.
Discussion
The increasing role of PSA as a screening tool for 
prostatic disease has led to an increase in the diagnosis 
of prostate cancer, with more cancers being detected at 
an earlier stage. The need for staging of prostate cancer 
is important for optimal management, which includes 
radical prostatectomy for organ-confined disease and 
androgen deprivation therapy for metastatic disease.
Forty-one percent of the patients in our study had skeletal 
metastases as assessed on bone scans using methods for 
which good reliability was demonstrated. This is over 
Figure 2: Box plot displaying summary statistics for PSA in cases 
with and without metastasis
Figure 3: Summary of frequency and percentage involvement of 
various sites of skeletal metastases
Table 1: Summary statistics for distribution of PSA 
in patients with and without skeletal metastases
Mean Median SD† Min Max
No 68.4 15.2 226.4 1 1,800
Yes 512.8 100 1101.5 1.02 7,000
†SD: Standard deviation
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twice the proportion seen in the systematic review by 
Abuzallouf et al. where 1,453 out of 8,644 patients (16.8%) 
had positive bone scans. The inclusion of solely native 
ethnic African patients in the present study may be a 
possible explanation for the large difference. Data from 
other dark skinned populations have shown higher 
prostate cancer incidence and mortality within men 
of African descent  that is consistent with a truly greater 
prevalence of the disease in this group.[1] Fifty-six percent 
of the patients in our study had a PSA level greater 
than or equal to 20 ng/mL while 44.3% had a PSA level 
below 20 ng/mL. A considerable difference is seen 
between the present findings, compared to those from 
the meta-analysis where 27.8% of the patients had a PSA 
level of greater than or equal to 20 ng/mL, and 72.2% 
had a PSA level of less than 20 ng/mL. This reflects the 
case mix and inclusion criteria in reported studies, with 
many reporting the results of evaluation for skeletal 
metastases at PSA levels less than 20 ng/mL.
The mean PSA level was five times higher in patients 
with skeletal metastases than those without skeletal 
metastases in the current study––a finding that is 
expected, considering that the incidence of skeletal 
metastases increases with an increase in the PSA level. 
Of the patients without metastases, most were in the 
low PSA group, as indicated by a median PSA value of 
15.2 ng/mL. Within the high PSA group, the median PSA 
was 86 ng/mL. An important observation with clinical 
implications in our sample is the wide distribution of 
PSA levels among patients with skeletal metastases, 
including those below 20 ng/mL.
We documented a higher prevalence of skeletal 
metastasis in the regional native ethnic African 
population relative to the typical global pattern, 
especially those with a low PSA level. Indeed, the 
prevalence of metastasis was considerably greater 
than that seen in East Asian studies and among Arab 
populations, which is consistent with the existing 
data that indicate that these ethnic groups have a 
lower incidence and mortality from prostate cancer.
[7-10] Five studies from the systematic review reported 
a prevalence of skeletal metastases above 10% at PSA 
levels below 20 ng/mL, with reported ranges from 11.7% 
to 15.9%.[11-15] The prevalence of skeletal metastasis in 
these studies is still noted to be somewhat lower than 
the current study population. A possible reason for this 
is the ethnic differences of patients in these studies from 
the current study, which exclusively evaluated native 
ethnic African males. Our findings are consistent with 
the conclusion that skeletal metastases from prostate 
cancer occur earlier in men of African descent, and 
that the biological aggressiveness of prostate cancer 
within this population may be higher than that seen 
within non-native ethnic African male populations. 
These findings are parallel to reports showing that the 
incidence of and mortality rates from prostate cancer 
within the east African region are high.[2]
In the current study, the spine, pelvis, and ribs were 
the most common sites of skeletal metastasis. The 
probable reasons for this include the fact that the 
above sites are abundant in cancellous bone, which 
has a rich blood supply. During the passage of blood 
through tight sinusoids in this bone structure, there is 
a slowing of blood flow allowing deposition of tumor 
cells. In addition, tethering proteins such as vascular 
cell adhesion molecule 1 (VCAM-1) are moderately 
expressed and interact with neoplastic cells, anchoring 
them to the bone.[16] This pathophysiological mechanism 
also explains why the upper and lower limbs are 
affected (32% and 20%, respectively); however, it does 
not explain why this is less than the previously described 
regions. A possible explanation is the conversion of red 
marrow, and subsequent reduction in blood supply to 
the bone marrow compared to the previously described 
areas where residual red marrow exists in relative 
abundance.
Conclusions
The results from the present study suggest that prostate 
cancer within the East African native male population 
demonstrates aggressive biological behavior, similar to 
that seen in African American populations. Based on 
our findings, we consider bone scans should be ordered 
for prostate cancer patients with PSA levels less than 
20 ng/mL, and in our setting those with levels less than 
10 ng/mL should also be investigated. The need for 
scanning is obviously greater if patients have coexisting 
risk factors for skeletal metastasis such as high Gleason’s 
scores or extra prostatic disease extension, and there is 
therefore, a role for further research in this field locally.
Establishing the infrastructure and logistics required 
to run a nuclear medicine facility are challenging in 
low-resource settings. Aspects of this are training and 
retention of specialist personnel, consistent procurement 
of radionuclide generators and radiopharmaceuticals, 
the maintenance of infrastructure that meets radiation 
safety standards, and the ability to sustain the service 
through realistic cost recovery and adequate volume 
of cases referred for investigation. We consider that 
the appropriate way forward is to concentrate such 
services within larger tertiary referral centers alongside 
arrangements to enable a wide access through effective 
referral linkages that deal with practical arrangements 
such as travel and accommodation. In sub-Saharan Africa, 
resourcing such developments may be best undertaken 
via public–private collaboration on cancer services using 
mechanisms such as service level agreements involving 
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partners at the regional as well as national levels, as for 
many countries undertaking these developments would 
be unrealistic. Furthermore, some countries are currently 
developing or implementing national cancer strategies 
so that related regional collaboration would be timely.
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Appendix 1
No. of cases OR† desired 
to be detected
Power to detect 
the desired OR
50 2 0.434
3 0.841
4 0.967
40 2 0.347
3 0.740
4 0.916
30 3 0.592
4 0.805
5 0.910
20 4 0.590
5 0.728
6 0.819
7 0.879
8 0.917
18 6 0.765
7 0.832
8 0.878
9 0.910
10 0.933
15 8 0.788
9 0.830
10 0.863
11 0.888
12 0.907
†OR: Odds ratio
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